183 related articles for article (PubMed ID: 21051656)
1. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
LaCroix AZ; Powles T; Osborne CK; Wolter K; Thompson JR; Thompson DD; Allred DC; Armstrong R; Cummings SR; Eastell R; Ensrud KE; Goss P; Lee A; Neven P; Reid DM; Curto M; Vukicevic S;
J Natl Cancer Inst; 2010 Nov; 102(22):1706-15. PubMed ID: 21051656
[TBL] [Abstract][Full Text] [Related]
2. Tipping the balance for the primary prevention of breast cancer.
Vogel VG
J Natl Cancer Inst; 2010 Nov; 102(22):1683-5. PubMed ID: 21051657
[No Abstract] [Full Text] [Related]
3. Lasofoxifene in postmenopausal women with osteoporosis.
Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
[TBL] [Abstract][Full Text] [Related]
4. Third-generation SERMs may face uphill battle.
Schmidt C
J Natl Cancer Inst; 2010 Nov; 102(22):1690-2. PubMed ID: 21060064
[No Abstract] [Full Text] [Related]
5. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
6. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
[TBL] [Abstract][Full Text] [Related]
7. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
8. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
9. Lasofoxifene for postmenopausal women with osteoporosis.
Silva-Fernández L; Andreu JL
N Engl J Med; 2010 Jun; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
[No Abstract] [Full Text] [Related]
10. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
11. Lasofoxifene in osteoporosis and its place in therapy.
Swan VJ; Hamilton CJ; Jamal SA
Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
[TBL] [Abstract][Full Text] [Related]
12. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
Gennari L
Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
[TBL] [Abstract][Full Text] [Related]
13. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
14. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
15. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
16. The rise of raloxifene and the fall of invasive breast cancer.
Jordan VC
J Natl Cancer Inst; 2008 Jun; 100(12):831-3. PubMed ID: 18544739
[No Abstract] [Full Text] [Related]
17. Lasofoxifene for postmenopausal women with osteoporosis.
Malozowski S
N Engl J Med; 2010 Jun; 362(23):2227; author reply 2228-9. PubMed ID: 20558377
[No Abstract] [Full Text] [Related]
18. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
19. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Archer DF
Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
[No Abstract] [Full Text] [Related]
20. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
